Yibing Ruan1, Anna Kovalchuk1, Aarthi Jayanthan1, Xueqing Lun1, Yoji Nagashima1, Olga Kovalchuk1, James R Wright1, Alfredo Pinto1, Adam Kirton1, Ronald Anderson1, Aru Narendran1. 1. Division of Pediatric Oncology, Alberta Children's Hospital and POETIC Laboratory for Preclinical and Drug Discovery Studies, University of Calgary, Calgary, Alberta, Canada (Y.R., A.J., X.L., R.A., A.N.); Department of Biological Sciences, University of Lethbridge, Lethbridge, Canada (A.K., O.K.); Department of Pathology, Yokohama City University School of Medicine and Division of Diagnostic Pathology, Tokyo Women's Medical University Hospital, Tokyo, Japan (Y.N.); Department of Pathology and Laboratory Medicine, Alberta Children's Hospital and Calgary Laboratory Services, Calgary, Canada (J.R.W., A.P.); Department of Neurology, Alberta Children's Hospital, Calgary, Canada (A.K.).
Abstract
BACKGROUND: Neurocutaneous melanocytosis (NCM) is a rare congenital disorder that presents with pigmented cell lesions of the brain or leptomeninges in children with large or multiple congenital melanocytic nevi. Although the exact pathological processes involved are currently unclear, NCM appears to arise from an abnormal development of melanoblasts or melanocyte precursors. Currently, it has an extremely poor prognosis due to rapid disease progression and lack of effective treatment modalities. METHODS: In this study, we report on an experimental approach to examining NCM cells by establishing subcutaneous tumors in nude mice, which can be further expanded for conducting molecular and drug sensitivity experiments. RESULTS: Analysis of the NRAS gene-coding sequences of an established NCM cell line (YP-MEL) and NCM patient cells revealed heterogeneity in NRAS Q61K that activated mutation and possibly consequential differential sensitivity to MEK inhibition. Gene expression studies were performed to compare the molecular profiles of NCM cells with normal skin fibroblasts. In vitro cytotoxicity screens of libraries of targeted small-molecule inhibitors revealed prospective agents for further evaluation. CONCLUSIONS: Our studies provide an experimental platform for the generation of NCM cells for preclinical studies and the production of molecular and in vitro data with which to identify druggable targets for the treatment.
BACKGROUND:Neurocutaneous melanocytosis (NCM) is a rare congenital disorder that presents with pigmented cell lesions of the brain or leptomeninges in children with large or multiple congenital melanocytic nevi. Although the exact pathological processes involved are currently unclear, NCM appears to arise from an abnormal development of melanoblasts or melanocyte precursors. Currently, it has an extremely poor prognosis due to rapid disease progression and lack of effective treatment modalities. METHODS: In this study, we report on an experimental approach to examining NCM cells by establishing subcutaneous tumors in nude mice, which can be further expanded for conducting molecular and drug sensitivity experiments. RESULTS: Analysis of the NRAS gene-coding sequences of an established NCM cell line (YP-MEL) and NCM patient cells revealed heterogeneity in NRASQ61K that activated mutation and possibly consequential differential sensitivity to MEK inhibition. Gene expression studies were performed to compare the molecular profiles of NCM cells with normal skin fibroblasts. In vitro cytotoxicity screens of libraries of targeted small-molecule inhibitors revealed prospective agents for further evaluation. CONCLUSIONS: Our studies provide an experimental platform for the generation of NCM cells for preclinical studies and the production of molecular and in vitro data with which to identify druggable targets for the treatment.
Authors: Anna Liza C Agero; Cristiane Benvenuto-Andrade; Stephen W Dusza; Allan C Halpern; Ashfaq A Marghoob Journal: J Am Acad Dermatol Date: 2005-10-07 Impact factor: 11.527
Authors: A Sorolla; A Yeramian; X Dolcet; A M Pérez de Santos; D Llobet; J A Schoenenberger; J M Casanova; X Soria; R Egido; A Llombart; R Vilella; X Matias-Guiu; R M Marti Journal: Br J Dermatol Date: 2008-01-17 Impact factor: 9.302
Authors: Martino Ruggieri; Agata Polizzi; Stefano Catanzaro; Manuela Lo Bianco; Andrea D Praticò; Concezio Di Rocco Journal: Childs Nerv Syst Date: 2020-10-13 Impact factor: 1.475
Authors: Dipanjan Basu; Cláudia M Salgado; Bruce Bauer; Yasmin Khakoo; Janki R Patel; Ryan M Hoehl; Dominique M Bertolini; Joie Zabec; Morgan R Brzozowski; Miguel Reyes-Múgica Journal: Cancer Genomics Proteomics Date: 2018 Jul-Aug Impact factor: 4.069
Authors: Giulia Angelino; Maria Debora De Pasquale; Luigi De Sio; Annalisa Serra; Luca Massimi; Rita De Vito; Antonio Marrazzo; Laura Lancella; Andrea Carai; Manila Antonelli; Felice Giangaspero; Marco Gessi; Laura Menchini; Laura Scarciolla; Daniela Longo; Angela Mastronuzzi Journal: BMC Cancer Date: 2016-07-20 Impact factor: 4.430